The Quest for a Lost Chinese Typewriter
Dr. Mullaney, a professor of Chinese history at Stanford University, had spent years searching the globe for Chinese typewriters, wondrous machines capable of printing thousands of Chinese characters while remaining small enough to keep on a desk.
The typewriter, 50 pounds of metal frame and levers, was one of a dying breed. If he didn't save it, would it wind up on a scrapheap?
It went into a suitcase and he took it back to California, where it joined a growing collection of Asian-language typing devices that he'd hunted down.
But there was one typewriter that Dr. Mullaney had little hope of ever finding: the MingKwai. Made by an eccentric Chinese linguist turned inventor living in Manhattan, the machine had mechanics that were a precursor to the systems almost everyone now uses to type in Chinese.
Only one — the prototype — was ever made.
'It was the one machine,' he said recently, 'which despite all my cold-calling, all my stalking, was absolutely, 100 percent, definitely gone.'
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET. The live webcast of the fireside chat may be accessed from the Investors section of Tenaya's website. An archived replay will be available on the Tenaya website for approximately 30 days following the live event. About Tenaya TherapeuticsTenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya's pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit Tenaya ContactsMichelle CorralVP, Corporate Communications and Investor RelationsIR@ InvestorsAnne-Marie FieldsPrecision AQ in to access your portfolio
Medscape
14 minutes ago
- Medscape
Does Getting Fit Guard Against Colorectal Cancer?
Evidence continues to mount that building cardiovascular fitness can help lower an individual's risk for colorectal cancer (CRC). The latest study — a sweeping analysis of 643,583 individuals, with more than 8000 cases of CRC and 10 years follow-up — found a consistent, inverse, and graded association between cardiorespiratory fitness (CRF) and the risk for the development of CRC — a benefit similar for men and women and across races. CRC risk was 9% lower for each 1-metabolic equivalent (MET) task increase in CRF, objectively measured by an exercise treadmill test. When assessed across CRF categories, there was a progressive decline in CRC risk with higher CRF, Aamir Ali, MD, and colleagues with Veterans Affairs Medical Center, Washington, DC, found. Compared with the least fit individuals (METs, 4.8), the CRC risk was 14% lower in those falling in the low-fit CRF category (METs, 7.3), 27% lower for moderately fit people (METs, 8.6), 41% lower for fit individuals (METs, 10.5), and 57% lower for high-fit individuals (METs, 13.6). Moderate CRF is attainable by most middle-aged and older individuals, by engaging in moderate-intensity physical activity such as brisk walking, which aligns with current national guidelines, the authors said. The study was published online on July 28 in Mayo Clinic Proceedings. The results dovetail with earlier work. For example, in the Cooper Center Longitudinal Study, men with high mid-life CRF had a 44% lower risk for CRC and a 32% lower risk of dying from cancer later in life men with low CRF. A recent meta-analysis for the World Cancer Research Fund estimated a 16% lower risk for colon cancer in people with the highest levels of recreational physical activity relative to those with the lowest levels. A recent UK Biobank analysis using accelerometers linked higher daily movement to a 26% reduction in risk across multiple cancers, including bowel cancer. Taken together, the data suggest that 'the more you exercise, the better your overall health is going to be — not just your cardiac fitness but also your overall risk of cancer,' Joel Saltzman, MD, medical oncologist at Cleveland Clinic Taussig Cancer Center, Cleveland, noted in an interview with Medscape Medical News . Can You Outrun CRC Risk? In the US, CRC is the second leading cause of cancer mortality, accounting for 51,896 deaths in 2019. The economic burden of CRC in the US is significant, topping $24 billion annually. And while the incidence of colon cancer has decreased in older individuals during the past 3 decades, the incidence in younger adults has nearly doubled during the same period, 'underscoring the limitations of screening programs and the critical need for risk factor modification,' Ali and colleagues wrote. 'There is good evidence that exercise and healthy lifestyle/diet have significant benefit overall and as well for some potential risk reduction for colon cancer,' David Johnson, MD, professor of medicine and chief of gastroenterology, Eastern Virginia Medical School in Norfolk, Virginia, told Medscape Medical News. 'There are clearly suggestions of why this makes sense via the beneficial effects of exercise and physical activity in CRC pathways including but not limited to regulation of inflammation and aberrant cell growth/cancer pathways,' Johnson said. He emphasized, however, that exercise and lifestyle are not the best way to prevent CRC. 'Appropriate screening, in particular by colonoscopy (by skilled physicians who meet high-quality performance national benchmarks) to detect and remove precancerous polyps, is the best approach for prevention,' Johnson said. 'At this point — albeit exercise is potentially helpful and a great general recommendation — my most current advice as an expert in the field, is that you cannot outrun CRC risk,' Johnson said. Can You Outrun CRC Recurrence? Prevention aside, the data thus far are even more supportive of risk reduction for patients who have had CRC and are targeting reduction of recurrence, Johnson said. Perhaps the most compelling study was recently published in The New England Journal of Medicine. The CHALLENGE trial enrolled patients with resected stage II or III colon cancer who had completed their adjuvant chemotherapy. Patients with recurrences within a year of diagnosis were excluded, as they were more likely to have highly aggressive, biologically active disease. Participants were randomized to receive healthcare education materials alone or in conjunction with a structured exercise program over a 3-year follow-up period. The focus of the exercise intervention was increasing recreational aerobic activity over baseline by at least 10 METs — essentially the equivalent of adding about 45-60 minutes of brisk walking or 25-30 minutes of jogging three to four times a week. At a median follow-up of nearly 8 years, exercise reduced the relative risk for disease recurrence, new primary cancer, or death by 28% ( P = .02). 'This benefit persisted — and even strengthened — over time, with disease-free survival increasing by 6.4 and 7.1 percentage points at 5 and 8 years, respectively,' Johnson noted in a Medscape commentary. The CHALLENGE results are 'very compelling,' Bishal Gyawali, MD, PhD, associate professor of oncology at Queen's University, Kingston, Ontario, Canada, noted in a separate Medscape commentary. 'If you compare these results with results from other trials, you'll see that this is a no-brainer. If this were a drug, you would want to use it today,' Gyawali said. Saltzman told Medscape Medical News patients often ask him what they can do to help prevent their cancer from coming back. 'I would sort of say, 'Well, eat a healthy diet and exercise,' but I didn't have a lot of good evidence to support it.' The CHALLENGE study provides 'the proof in the pudding.' With these strong data, 'it almost feels like I should be able to write a prescription for my patient to join an exercise program and that their insurance should cover it,' Saltzman said.
Medscape
14 minutes ago
- Medscape
Restricted Drug Coverage Tied to Higher Risk for MS Relapse
Restricted coverage of medications for relapsing-remitting multiple sclerosis (MS) was associated with a higher risk for relapse, a new study showed. Patients with MS enrolled in Medicare Advantage Prescription Drug plans (MA-PDs) with broader formulary coverage were 8%-12% less likely to experience an MS relapse, while those in broad-coverage stand-alone prescription drug plans (PDPs) had 6%-9% lower odds of relapse. The findings highlight that cost-saving measures used by pharmacy benefit managers to exclude certain drugs from formularies can have tangible negative outcomes, especially for patients with complex or chronic conditions. 'Patients with MS may need to try multiple drugs to find what works best for them. Broad formulary exclusions ultimately undermine the individualized care these patients need,' said lead author Geoffrey Joyce, PhD, director of Health Policy at the Schaeffer Center and chair in the Department of Pharmaceutical and Health Economics at the University of Southern California in Los Angeles, in a news release. The study was published online on August 1 in JAMA Network Open . Cost-Cutting May Come at Patients' Expense Part of the push to exclude certain medications or seek rebates is due to the increasing number of therapies within the same class, the investigators noted. Competition among manufacturers allows pharmacy benefit managers to negotiate better prices via the exclusion of more costly drugs from their formulary. This can prevent some patients from getting their prescribed medication, such as drugs for relapsing-remitting MS, which are not protected by Medicare's Part D classifications. A 2024 study showed that Medicare Part D plan formularies excluded an average 44.7% of brand-only compounds and that drug restrictions for this plan increased over the study period of 2011-2020. To investigate whether such exclusions were associated with relapse episodes for MS patients, the researchers analyzed Medicare data of 50,162 beneficiaries in PDPs (mean age, 58.5 years; 74.9% women; 80.7% White) and 34,708 in MA-PDs (mean age, 58.2 years; 77.2% women; 75.5% White). More MS Therapies, Less Coverage The study timeline was divided into quarters, starting in 2019 (2020 Q2 was left out as a result of COVID-19 disruptions). To gauge patient outcomes, the first four quarters were used as a baseline period and the fifth quarter as the follow-up period. Beneficiary severity of MS was evaluated using the expanded disability status scale derived from the disability/impairment scores. The researchers looked at 15 disease-modifying therapies (DMTs) on the market from 2018 to 2022. In their analysis, the Medicare plans were assumed to cover the five intravenous MS DMTs. The amount of on-formulary MS DMTs was calculated to give a four-quarter moving average and DMTs were classified as on formulary if their generic name was covered by the plans. Plans were deemed low coverage if the four-quarter moving average of DMTs was below the plan's median during baseline. For the follow-up portion, logistic regression models were employed for MS relapse episodes, and Poisson or negative binomial regression models were used for nonbinary dependent variables such as the number of relapse episodes. Multivariable regression models were used to control for patient characteristics. PDPs typically covered only four of the 15 drugs across four classes, while MA-PDs covered double this across five classes. Many oral and injectable DMTs were frequently not covered by plans particularly in stand-alone plans, such as teriflunomide (amount of plans without compound on formulary: PDP, 87.7%; MA-DP, 43.3%), ofatumumab (PDP, 99.6%; MA-DP, 86%), and interferon beta-1a (PDP, 86.5%; MA-DP, 41.4%). The rate of any MS relapse was higher for low-coverage plans compared with broader coverage plans for PDPs (10.6% vs 9.5%; odds ratio [OR], 0.88 [95% CI, 0.85-0.91]) and MA-PDs (7.8% vs 6.9%; OR, 0.88 [95% CI, 0.84-0.92]). MS is most commonly diagnosed between 20 and 40 years of age — a limitation of the study was that most Medicare beneficiaries are older than this cohort. Other limitations were potential administration errors inherent in health claims data and that quarterly periods might not be sufficient to fully evaluate the relationship between formulary coverage and relapse episodes. The researchers noted that the effect of such restrictions might be exacerbated for Part D beneficiaries, thanks to the new $2000 annual cap on out-of-pocket drug expenses. 'Innovative new treatments have made it possible to slow or prevent symptoms for some of the most complex diseases, but costs remain a challenge,' Joyce said. 'We must find sustainable ways to ensure all patients can access these potentially life-changing treatments.'
